SY-5609, a highly potent and selective oral CDK7 inhibitor, exhibits robust antitumor activity in preclinical models of KRAS mutant cancers as a single agent and in combination with chemotherapy

ANNALS OF ONCOLOGY

ELSEVIER

1. Syros Pharmaceuticals